378 related articles for article (PubMed ID: 25134314)
1. Basal cell carcinoma: pathophysiology.
Sehgal VN; Chatterjee K; Pandhi D; Khurana A
Skinmed; 2014; 12(3):176-81. PubMed ID: 25134314
[TBL] [Abstract][Full Text] [Related]
2. A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy.
Sánchez-Danés A; Larsimont JC; Liagre M; Muñoz-Couselo E; Lapouge G; Brisebarre A; Dubois C; Suppa M; Sukumaran V; Del Marmol V; Tabernero J; Blanpain C
Nature; 2018 Oct; 562(7727):434-438. PubMed ID: 30297799
[TBL] [Abstract][Full Text] [Related]
3. Hedgehog Pathway Inhibition.
Sekulic A; Von Hoff D
Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418
[TBL] [Abstract][Full Text] [Related]
4. Discovery and preclinical development of vismodegib.
Gould SE; Low JA; Marsters JC; Robarge K; Rubin LL; de Sauvage FJ; Sutherlin DP; Wong H; Yauch RL
Expert Opin Drug Discov; 2014 Aug; 9(8):969-84. PubMed ID: 24857041
[TBL] [Abstract][Full Text] [Related]
5. Protein kinase A activation inhibits oncogenic Sonic hedgehog signalling and suppresses basal cell carcinoma of the skin.
Makinodan E; Marneros AG
Exp Dermatol; 2012 Nov; 21(11):847-52. PubMed ID: 23163650
[TBL] [Abstract][Full Text] [Related]
6. Locally advanced and metastatic basal cell carcinoma: molecular pathways, treatment options and new targeted therapies.
Ruiz Salas V; Alegre M; Garcés JR; Puig L
Expert Rev Anticancer Ther; 2014 Jun; 14(6):741-9. PubMed ID: 24611655
[TBL] [Abstract][Full Text] [Related]
7. Sonic hedgehog pathway dysregulation in skin basal-cell carcinoma of a Polish population.
Lesiak A; Sobolewska-Sztychny D; Danilewicz M; Rogowski-Tylman M; Sysa-Jedrzejowska A; Sobjanek M; Olejniczak-Staruch I; Narbutt J
Folia Histochem Cytobiol; 2013; 51(3):219-24. PubMed ID: 24203628
[TBL] [Abstract][Full Text] [Related]
8. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
Proctor AE; Thompson LA; O'Bryant CL
Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
[TBL] [Abstract][Full Text] [Related]
9. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
10. Expression of sonic hedgehog signal transducers, patched and smoothened, in human basal cell carcinoma.
Tojo M; Mori T; Kiyosawa H; Honma Y; Tanno Y; Kanazawa KY; Yokoya S; Kaneko F; Wanaka A
Pathol Int; 1999 Aug; 49(8):687-94. PubMed ID: 10504535
[TBL] [Abstract][Full Text] [Related]
11. Hedgehog- and mTOR-targeted therapies for advanced basal cell carcinomas.
Piérard-Franchimont C; Hermanns-Lê T; Paquet P; Herfs M; Delvenne P; Piérard GE
Future Oncol; 2015 Nov; 11(22):2997-3002. PubMed ID: 26437034
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
[TBL] [Abstract][Full Text] [Related]
13. Targeting the hedgehog pathway to treat basal cell carcinoma.
Geeraert P; Williams JS; Brownell I
J Drugs Dermatol; 2013 May; 12(5):519-23. PubMed ID: 23652945
[TBL] [Abstract][Full Text] [Related]
14. Sonidegib phosphate: new approval for basal cell carcinoma.
Tibes R
Drugs Today (Barc); 2016 May; 52(5):295-303. PubMed ID: 27376162
[TBL] [Abstract][Full Text] [Related]
15. Relation between sonic hedgehog pathway gene polymorphisms and basal cell carcinoma development in the Polish population.
Lesiak A; Sobolewska-Sztychny D; Majak P; Sobjanek M; Wodz K; Sygut KP; Majsterek I; Wozniacka A; Narbutt J
Arch Dermatol Res; 2016 Jan; 308(1):39-47. PubMed ID: 26590974
[TBL] [Abstract][Full Text] [Related]
16. A cell identity switch allows residual BCC to survive Hedgehog pathway inhibition.
Biehs B; Dijkgraaf GJP; Piskol R; Alicke B; Boumahdi S; Peale F; Gould SE; de Sauvage FJ
Nature; 2018 Oct; 562(7727):429-433. PubMed ID: 30297801
[TBL] [Abstract][Full Text] [Related]
17. Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin.
Danhof R; Lewis K; Brown M
Am J Clin Dermatol; 2018 Apr; 19(2):195-207. PubMed ID: 28887802
[TBL] [Abstract][Full Text] [Related]
18. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma.
Pricl S; Cortelazzi B; Dal Col V; Marson D; Laurini E; Fermeglia M; Licitra L; Pilotti S; Bossi P; Perrone F
Mol Oncol; 2015 Feb; 9(2):389-97. PubMed ID: 25306392
[TBL] [Abstract][Full Text] [Related]
19. Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma.
Leavitt E; Lask G; Martin S
Curr Treat Options Oncol; 2019 Nov; 20(11):84. PubMed ID: 31773379
[TBL] [Abstract][Full Text] [Related]
20. Smoothened inhibitors in the treatment of advanced basal cell carcinomas.
Kunstfeld R
Curr Opin Oncol; 2014 Mar; 26(2):184-95. PubMed ID: 24469022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
